Sol-Gel Technologies Ltd. (SLGL)

Nasdaq: SLGL · Pharmaceutical Preparations · filing with the SEC since 2016

Full chart Alerts Compare

Grade6.3

◀ Past 6.6● Present 6.4▶ Future 6.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$19.4M+68.0%

Net income-$6.1M+42.1%

Earnings per share$-2.19+42.2%

Operating cash flow$322,000+102.3%

Cash$11.0M-43.4%

Debtn/a

Shareholders’ equity$22.8M-20.9%

Shares, diluted2,785,875+0.0%

Return on equity-26.9%

The recordfrom its filings

Filings in 202650

Newest filingNov 12 · 6-K

Annual reportMar 19, 2026

Quarterly reportn/a

Next report due20-F by Apr 30

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted40

Filer categoryNon-accelerated filer

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Oct 6, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 30, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 17, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 14, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 9, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Aug 31, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Sol-Gel Technologies Ltd. is classed by the SEC under Pharmaceutical Preparations (industry code 2834). License was 96% of fiscal 2025 revenue.

Newest on the record

Interim report, foreign filer on Nov 12. Before it, large holder update, amended on Nov 6.

What is due next

The 20-F for the period to Dec 31, 2026, due by Apr 30, 2027.

About SLGL

Sol-Gel Technologies Ltd. is classed by the SEC under Pharmaceutical Preparations (industry code 2834). In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $19 million and a loss of $6.1 million (its filed statements).

IndustryPharmaceutical Preparations

Business modelPre-revenue company

ExchangeNasdaq

Filing since2016

Fiscal year endsDec 31

SEC number (CIK)1684693

Peers on fileVERU, TLPH, PDSB, CPHI

Who runs it

Financial performance

In fiscal 2025 Sol-Gel Technologies’s revenue was $19.39 million, up 68.0% from $11.54 million the year before. It made a net loss of $6.13 million.

Annual report, filed Mar 19, 2026.

Financial statements

The grade

Sol-Gel Technologies grades 6.3 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past6.6

● Present6.4

▶ Future6.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton SLGL · research, not advice